SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) June 9, 2004
INCARA PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
0-50481 | 56-1953785 | |
(Commission File Number) | (IRS Employer ID Number) |
P.O. Box 14287
79 T. W. Alexander Drive
4401 Research Commons, Suite 200
Research Triangle Park, North Carolina 27709
(Address of principal executive offices) (Zip Code)
Registrants telephone number, including area code (919) 558-8688
Item 5. Other Events and Regulation FD Disclosure
On June 9, 2004, Incara Pharmaceuticals Corporation issued a press release announcing the appointment of James D. Crapo as its Chief Executive Officer, effective July 1, 2004. A copy of this press release is attached as an exhibit.
Item 7. Financial Statements and Exhibits
(c) | Exhibits |
Exhibit 99.1 | Press release dated June 9, 2004 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION | ||
Date: June 9, 2004 |
||
/s/ Richard W. Reichow | ||
Richard W. Reichow | ||
Executive Vice President and Chief Financial Officer |